Advertisement

Topics

CP-461 in the Treatment of Patients with Advanced Melanoma

2014-07-23 21:52:24 | BioPortfolio

Summary

The purpose of this study is to determine the efficacy of CP-461 given twice daily orally in patients with advanced or metastatic malignant melanoma and to evaluate the safety profile of CP-461 in this patient population.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Malignant Melanoma

Intervention

CP-461

Location

Columbia Presbyterian Medical Center
New York
New York
United States
10032

Status

Terminated

Source

OSI Pharmaceuticals

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:52:24-0400

Clinical Trials [1369 Associated Clinical Trials listed on BioPortfolio]

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

The purpose of this research study is to find out whether JX-594 is safe and effective for treating surgically unresectable malignant melanoma.

The Identification of Novel Prognostic Markers in Melanoma

The purpose of this project is to analyze tumour tissue from a group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital.

Clinical Study of Previously Untreated Patients With Malignant Melanoma

Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until comple...

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

The primary purpose of the study is to determine the proportion of patients without progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are taking RTA ...

Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

This is a Phase I, open-label, multicenter, pharmacokinetic study of MDX-010 in up to 90 evaluable subjects with surgically unresectable malignant melanoma.

PubMed Articles [2460 Associated PubMed Articles listed on BioPortfolio]

Clinical outcomes of primary intracranial malignant melanoma and metastatic intracranial malignant melanoma.

Primary intracranial malignant melanoma (PIMM) is extremely rare central nervous system (CNS) tumor and known for only composed 0.07% of the CNS tumors. PIMM composed only 1% of malignant melanoma and...

Primary malignant melanoma of the female urethra: Report of a rare neoplasm of the urinary tract.

Melanoma is a malignant tumor that can affect any area of the anatomical economy. Its occurance in the female urethra is extremely rare. We report a case of primary malignant urethral melanoma develop...

A review of primary malignant melanoma arising in an ovarian cystic teratoma.

Primary malignant melanoma arising in an ovarian cystic teratoma is exceedingly rare event with an estimated incidence of 0.2-0.8%. So far, there have been approximately only 47 relevant reports. We r...

Rare germline variants in known melanoma susceptibility genes in familial melanoma.

Known high-risk cutaneous malignant melanoma (CMM) genes account for melanoma risk in 

Primary Malignant Melanoma in the Pineal Region: Case Report and Literature Review.

 Primary pineal malignant melanoma is a rare type of primary central nervous system melanoma with only 19 cases reported in the literature.

Medical and Biotech [MESH] Definitions

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.

Clinically atypical nevi (usually exceeding 5 mm in diameter and having variable pigmentation and ill defined borders) with an increased risk for development of non-familial cutaneous malignant melanoma. Biopsies show melanocytic dysplasia. Nevi are clinically and histologically identical to the precursor lesions for melanoma in the B-K mole syndrome. (Stedman, 25th ed)

More From BioPortfolio on "CP-461 in the Treatment of Patients with Advanced Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...


Searches Linking to this Trial